Table 2.
Effect estimates for lead single-nucleotide polymorphism
| Locus | Gene | SNP | DR2 | Minor Allele | MAF Patients | MAF Controls | OR | 95% CI | P Value |
|---|---|---|---|---|---|---|---|---|---|
| 6p21.3 | HLA-DQB1 | rs9273542 | 0.89 | T | 0.51 | 0.24 | 3.39 | 2.86 to 4.03 | 1.59×10−43 |
| 6q22.1 | CALHM6/FAM26F | rs2637678 | 0.96 | C | 0.26 | 0.40 | 0.51 | 0.44 to 0.60 | 1.27×10−17 |
| 4q13.3 | PARM1 | rs10518133 | 0.93 | A | 0.12 | 0.06 | 1.96 | 1.57 to 2.45 | 2.50×10−8 |
Minor allele frequencies (MAFs) and odds ratios (ORs) with 95% confidence intervals (95% CIs) for each of the minor alleles of the lead single-nucleotide polymorphisms (SNPs) from the three loci achieving genome-wide significance. Dosage R2 (DR2) indicates the Beagle imputation quality score.